Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Does HLA-DQA1*05 carriage have a greater impact on the outcome of infliximab therapy for isolated small-bowel Crohn's disease?

International journal of immunogenetics - 1 Dec 2024

Wu Juan, Zhu Nannan, Hu Jing, Zhang Chenyu, Fang Yuanyuan, Wu Yumei, Shi Yongrong, Liu Qiuyuan, Ding Hao, Mei Qiao, Bai Bingqing, Han Wei

Abstract excerpt

Carriage of HLA-DQA1*05 is thought to increase the formation of anti-tumour necrosis factor alpha (TNF-α) antibodies, reducing the drug efficacy in Crohn's disease (CD) patients. However, little data are currently available for small-bowel Crohn's disease (SB-CD). A specific assessment of the impact of HLA-DQA1*05 on the clinical response to treatment with infliximab (IFX), a TNF-α antagonists, in SB-CD patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Crohn Disease
Share to Gastrointestinal Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HLA-DQ alpha-Chains

Share to Infliximab

Share to Intestine, Small

Share to Treatment Outcome

Share to Tumor Necrosis Factor-alpha

Share to Young Adult

Source

Identifiers

PMID: 39387318
DOI: 10.1111/iji.12696

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Does HLA-DQA1*05 carriage have a greater impact on the outcome of infliximab therapy for isolated small-bowel Crohn's disease?PMID 39387318Read ↗

Association between genetic variants and development of antibodies to infliximab: A cross-sectional study in Chinese patients with Crohn’s diseaseSemantic proximity Read ↗

HLA-DQB1*03:01 and HLA-DQA1*05:05 as key genetic determinants of infliximab response and immunogenicity in Japanese patients with inflammatory bowel disease.Semantic proximity Read ↗

HLA-DQA1*05 Carriage is Associated with treatment failure and the induction of anti-IFX antibodies in IBD patientsSemantic proximity Read ↗

Divergent effects of HLA-DQA1:p.Gln198Glu on trajectory in inflammatory bowel diseaseSemantic proximity Read ↗

Molecular Insight into the Role of HLA Genotypes in Immunogenicity and Secondary Refractoriness to Anti-TNF Therapy in IBD PatientsSemantic proximity Read ↗

Extended Analysis Identifies Drug-Specific Association of 2 Distinct HLA Class II Haplotypes for Development of Immunogenicity to Adalimumab and InfliximabSemantic proximity Read ↗

The HLA-DQA1*05 genotype does not influence the clinical response to ustekinumab and vedolizumab.Semantic proximity Read ↗

Revisiting HLA-DQA1*05 in Asian inflammatory bowel disease cohorts: Ethnic variations in genetic susceptibility to immunogenicity.Semantic proximity Read ↗

HLA-DQA1*05 is associated with the development of antibodies to anti-TNF therapySemantic proximity Read ↗

Impact of HLA-DQA1*05 Genotype in Immunogenicity and Failure to Treatment with Tumour Necrosis Factor-alpha Antagonists in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.Semantic proximity Read ↗

Endoscopic features and genetic background of inflammatory bowel disease complicated with Takayasu arteritis.Semantic proximity Read ↗

Genetic Polymorphisms on TNFA, TNFRSF1A, and TNFRSF1B Genes Predict the Effectiveness of Anti-TNF-α Treatment in Inflammatory Bowel Disease PatientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.